LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Position & Policy Recommendations to support EU ATMP Innovation

09/03/2020
WHITE PAPER

EuropaBio Position & Policy Recommendations to support EU ATMP Innovation

Europe has been a pioneer in the field of Advanced Therapy Medicinal Products (ATMPs) in terms of their development, authorisation, and regulation, thereby supporting patient access to these life-changing therapies. Between Jan. 2014 - Jun. 2019, 323 investigational clinical trials were initiated in Europe. However, this is less than half of what was observed in North America and Asia, with the number of new clinical trials increasing by <2% in Europe versus 36% and 28% in North America and Asia, respectively.1 To ensure the EU remains a leader in ATMP innovation, this paper outlines and elaborates EuropaBio’s position and policy recommendations to the European Commission (EC) across three key focus areas.

Clinical Trial Requirements
There is significant clinical trial complexity in the EU owing to Member States own interpretation of Clinical Trial Authorisation (CTA) legislation. This complexity creates confusion for ATMP developers and can lead to significant delays of planned trials, decreasing the attractiveness of conducting such trials in the EU. The upcoming Clinical Trial Regulation (CTR) (EU) No 536/2014 aims to promote the implementation of a harmonised CTA dossier and review timelines adopted by all Member States. However, EuropaBio is concerned that ATMP products will fall out of the CTR process owing to unrealistic review and response timelines as well as a submission portal that is not fit for purpose for ATMPs. As such, it is recommended that the EC and Clinical Trials Facilitation and Coordination Group (CTFG) build upon the learnings from the Voluntary Harmonised Procedure (VHP) for clinical trials and conduct ATMP-specific pilots to identify and resolve potential issues prior to wide-spread rollout of the CTR. Furthermore, enhanced centralised scientific advice procedures that allow for rapid advice on par with procedures in other jurisdictions, specifically the US, are requested to support timely EU involvement in global development programmes.

Genetically Modified Organism (GMO) Requirements
ATMPs that consist of or contain GMO are required to undergo additional approval procedures by GMO competent authorities in each Member State prior to CTA. This regulatory framework was not designed for pharmaceuticals and is not standardised across Member States resulting in developers undergoing multiple, inefficient and redundant procedures which are costly and can lead to significant delays to development programs. A single, networked approach conducted in parallel to CTA assessments is desired with the upcoming CTR providing an opportunity for the EC and CTFG to work with GMO authorities to achieve this. EuropaBio would like to collaboratively explore with the EC whether GMO requirements are appropriate for medicines given the current state of knowledge as well as how duplication between medicines and environmental agencies can be avoided to ensure optimised processes are in place to handle the increasing number of these products under development.

Optimised Evidence Requirements Including Real World Evidence (RWE)
It is often not possible to conduct large, randomised controlled clinical trials for ATMPs leading to uncertainty regarding their authorisation and reimbursement. However, RWE can be leveraged to complement ATMP clinical trial data and provide higher levels of confidence at the time of pre- and post-Marketing Authorisation (MA) decisions. There are no mature and relevant guidelines worldwide that clearly define the scope of application of RWE to drug development and there is therefore an opportunity for the EU to become a leading voice in defining its optimal use. EuropaBio recommends that a permanent working structure and information exchange platform is developed between the European Medicines Agency (EMA), national Heath Technology Assessment (HTA) bodies and payers with the intention to collect and utilise ‘’universal evidence,’’ i.e. data that supports the different needs of all stakeholders. This group would be tasked with initiating reviews and demonstration projects that ultimately allow for guidelines to be developed for the systematic integration of RWE to enhance drug development, authorisation and reimbursement processes.

Download the file below to read the full document.

EuropaBio Position & Policy Recommendations to support EU ATMP Innovation


Download
2020_03_H_WP_EuropaBio-ATMP-WhitepaperDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.